Results 321 to 330 of about 5,634,975 (396)

Understanding the Drug-Drug Interaction

open access: yesJournal of the Korean Medical Association, 2006
openaire   +2 more sources

ATG4B is required for mTORC1‐mediated anabolic activity and is associated with clinical outcomes in non‐small cell lung cancer

open access: yesFEBS Open Bio, EarlyView.
The relationship between anabolic and catabolic processes governing lung cancer cell growth is nuanced. We show that ATG4B, an autophagy regulator, is elevated in lung cancer and that high ATG4B is associated with worse patient outcomes. Targeting ATG4B in cells reduces growth, protein synthesis, and mTORC1 activity, demonstrating a new relationship ...
Patrick J. Ryan   +6 more
wiley   +1 more source

Improving the Working Models for Drug-Drug Interactions: Impact on Preclinical and Clinical Drug Development. [PDF]

open access: yesPharmaceutics
Nguyen J   +6 more
europepmc   +1 more source

Research progress on the metabolic transformation of Shenling Baizhu San under the influence of the gut microbiota

open access: yesAdvanced Chinese Medicine, EarlyView.
Abstract The gut microbiota plays a pivotal role in maintaining host metabolic homeostasis and overall physiological functions. Shenling Baizhu San (SLBZS), a time‐honored classical prescription for tonifying Qi, strengthening the spleen, removing dampness, and arresting diarrhea, has shown broad clinical efficacy in digestive disorders.
Jinlan Di, Xiaochun Zhang
wiley   +1 more source

Long‐Term Temporal Profile of Motor Recovery After Intracerebral Hemorrhage

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Limited data is available to describe the temporal profile of long‐term recovery over 1 year after the stroke in patients with spontaneous intracerebral hemorrhage (ICH). Methods A registered multicentral cohort was conducted to consecutively include non‐herniated supratentorial ICH patients from November 2013 to January 2023 ...
Yan Zheng   +24 more
wiley   +1 more source

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy